The gene decoding company that decided Asia deserved a reference chip of its own.
The mark of a company that reads DNA for a living. A saliva tube goes in one end; a report on health, ability and nutrition comes out the other.
Here is a thing about genetic testing that nobody advertises: the reference data underneath most consumer DNA tests was built largely from people of European descent. This is not a conspiracy. It is a sampling accident that hardened into an industry default. And it means that if you are one of the roughly 4.5 billion people who live in Asia, a lot of the machinery reading your genome is, quietly, reading it against someone else's.
Genetica's entire premise is that this gap is a product opportunity rather than a footnote. Founded in San Francisco in 2018 by Tuan Cao, Mat Falkowski and Duyen Bui, the company set out to do the unglamorous work of building a gene decoding chip - manufactured with Illumina and Thermo Fisher - specifically for Asian genomes. Then it moved most of the actual testing to where the customers are, running its consumer business out of Ho Chi Minh City, Vietnam.
The mechanics are pleasingly simple from the customer's side. You spit into a tube. You mail it back. Somewhere in a CLIA- and CAP-certified lab, hundreds of genes get read, an AI does the pattern work, and a team of scientists affiliated with UCSF, Harvard, Stanford and Cornell sits between the raw output and the report you eventually open. What comes back is not ancestry trivia. It is a set of claims about health risk, innate ability, behavior, nutrition and fitness - the sort of thing you might actually make a decision on.
"Help optimize the development, and protect the healthy life, of you and your family."
— Genetica's stated missionReads 200+ genes from a child's saliva to report on innate ability, behavior and development - the version of the test that parents tend to buy first.
Health, behavior and ability reports covering disease risk and lifestyle, aimed at people who want the data before they need it.
Gene-based diet and exercise recommendations - the practical, day-to-day translation layer on top of the raw genetics.
Screening for inherited cancer risk, built around the idea that earlier knowledge buys earlier options.
One-on-one sessions with experts to interpret a report and plan next steps, because a PDF full of markers is not the same as a decision.
The clever part of Genetica is not only the chip. It is the distribution.
Consumer genomics has a well-known problem: the science is exciting and the sales cycle is not. Convincing a household to spit in a tube and pay for the privilege is a marketing problem more than a laboratory one. Genetica's answer has been to meet customers where they already are. It partnered with Con Cung, a Vietnamese mother-and-baby retail chain, to sell gene decoding for children alongside the strollers and formula. It signed multi-year deals with banks - SeABank and later MSB - so that gene decoding shows up as a customer perk rather than a cold purchase.
It is a direct-to-consumer model with a B2B spine: the tests are bought by families, but they are distributed through retailers, banks and healthcare partners who already have the relationship. There is also a more speculative thread - a collaboration with the Oasis Network on private, blockchain-secured genome sequencing, which is either the future of genomic data ownership or a very on-trend footnote, depending on how the decade goes.
Dr. Tuan Cao, co-founder and CEO, is the public face of the company and also of its sister effort, LIFE AI. His pitch is consistent: use genetic decoding and AI to build personalized, preventive healthcare for Asian populations, and do it with the same scientific rigor as a US lab. He has been featured in JoongAng Ilbo, one of South Korea's major national newspapers, appeared on Korea's NBN TV, and spoken at the Avalanche Summit in London. Co-founders Mat Falkowski and Duyen Bui round out the founding team.
"American technology genetic testing - built for Asians."
— Genetica's positioning, in eight wordsThe consumer genomics field is crowded with familiar names - 23andMe, AncestryDNA, Circle DNA, BGI Group - most of which optimized for scale in Western markets or for ancestry as the hook. Genetica's wager is narrower and, arguably, sturdier: pick a population that the incumbents treated as an afterthought, build the tooling that population actually needs, and distribute through partners who already have its trust. Whether that is a durable moat or a head start is the open question. But the gap it is aiming at is real, measurable, and largely unclaimed - and there are worse places for a young company to plant a flag.